Trial Profile
A phase II study of ONTAK (denileukin diftitox, DABIL-2) in patients with fludarabine-refractory B-cell chronic lymphocytic leukemia [CLL]
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Denileukin diftitox (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 01 Sep 2005 New trial record.